Ethical policies of Journal of Pharmaceutical Investigation

**Statement of Human and Animal Right, or Statement of Informed Consent** should be included in the Method sections if these items are related to the experimental content of the manuscript. In case of not relating to the use of Animal Right, the content must be added in the Acknowledgement section as described in the ‘Checklist’ and ‘Instructions for Authors’. For the publication of Bioequivalence Study, the guideline for ethics of volunteers was described in the ‘Instructions for Authors’ in detail. That is, it must include experimental design, number of volunteers, washout period, blood sampling method and time intervals, statistical method for bioequivalence tests, and the institutional review board approval number and/or protocol number. These parts will be checked in detail in the review process.

State of Human and Animal Rights: Research on human subjects must be approved by an appropriate Institutional Review Board and comply with all relevant regulations. In case of using experimental animals, authors should state the procedures used for animal care and handling. Some of the examples are showed below:

- This article does not contain any studies with human or animal subjects performed by the any of the authors;
- All institutional and national guidelines for the care and use of laboratory animals were followed.

Statement of Informed Consent: It should be stated that all the studies are performed in accordance with the ethical standards by the principles of the Declaration of Helsinki. A statement describing Institutional Review Board approval, consent procedures and that all human participants gave written informed consent must describe in the methods. For the policies on the research and publication ethics not stated in this instruction, International Standards for Editors and Authors (http://publicationethics.org/international-standards-editors-and-authors) can be applied.
Editorial Review Policy

The Editorial Committee consists of 3 editorial bodies; Managing Editor (ME), Associate Editor (AE) under the Editor-in-Chief (EiC). The JPI uses a fully web-enabled manuscript submission and review system (https: //www. editorialmanager.com/jpin/). This system offers authors with the option to track the real-time review process of their manuscripts. The ME conducts a technical check of manuscripts (MS), and, if necessary, sends an incomplete MS back to authors. The ME assigns the technically checked MS to EiC, who then conducts a scientific screening of the MS. Thereafter, the EiC (1) assigns an AE as a decision maker, (2) proceeds with the invitation of reviewers without further assignment, or (3) makes an immediate decision. The AE invites 2 peer reviewers (3 reviewers for a review article) and confirms if the reviewer agrees with reviewing the assigned MS within 3 days. The reviewing process is completed within 7 days until the reviewer send the review results back to the EiC. The AE informs the authors of the review results collected and the final decision results.

Author submits the revised MS online, and the ME receives and examines incoming revised submissions. The ME assigns MS to previous handling editor for the cycling of MS review system. Before submitting the final table of the Content of the Journal to the Publisher, a round-table meeting is organized bimonthly to discuss all issues brought up during the review or especially pending decision and problematic articles.

All submitted MS are basically screened by Medline and Google Scholar Search Functions available in the JPI Editorial site for the examination of plagiarism and duplicate publication. The MS with a higher score, greater than 80% will be further compared in detail. The conflict of interest, the statement of informed consent, and the statement of human and animal rights will be also intensively examined in the 3 levels of ME, AE, and EiC. If not provided, authors are requested to do so. Any MS with serious problems, such as plagiarism, data fabrication, or falsification are rejected. When these problems are found after acceptance, the final conclusion for manuscript retraction is made in the meeting of Editorial committee. We also support language editing for non-English speaking authors through collaboration with Edanz, in order to stimulate more submissions of MS from non-English speaking authors. English support is also one of the important responsibilities in editorial process of the AE, EiC, and reviewers.
Journal of Pharmaceutical Investigation
Editor-in-Chief: Han, H.-K.
ISSN: 2093-5552 (print version)
ISSN: 2093-6214 (electronic version)
Journal no. 40005